Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan

Saudi Medical Journal

Volumn 29, Issue 10, 2008, Pages 1423-1428

  Abdel Aal, Nazik M ^a   Ahmad, Azmi T ^a   Froelicher, Erika S ^a   Batieha, Anwar M S ^b   Hamza, Musdaq M ^a   Ajlouni, Kamel M ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BEHAVIOR THERAPY; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; JORDAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PATIENT EDUCATION; PREDICTION; PREVALENCE; SEX DIFFERENCE; BLOOD; MIDDLE AGED; RISK FACTOR; SEX RATIO;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; JORDAN; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION;

EID: 58749083710     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease studies. Lancet 1997; 349: 1269-1276.
2. Sievers ML, Nelson RG, Knowler WC, Bennett PH. Impact of NIDDM on mortality and causes of death in Pima Indians. Impact of NIDDM on mortaity & causes of death in pima Indians. Diabetes Care 1992; 15: 1541-1549.
3. American Diabeter Association. Diabetes and cardiovascular disease review. Issue 3. Alexandria (VA): American College of Cardiology; 2002. Available from URL: Www.diabetes.org.
4. Stamber J, Vaccaro O, Neaton JD. Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
5. American Diabetes Association. Annual Meeting, 1999: More on cardiovascular disease. Diabetes Care 2000; 23: 845-852.
6. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. Current concepts. JAMA 1990; 264: 3047-3052.
7. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heary disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234,
8. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014-1019.
9. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27: Suppl 1: S68-S71.
10. Al-Adani A, Memon A, Suresh A. Pattern and determinants of dyslipidaemia in type 2 diabetes mellitus patients in Kuwait. Acta Diabetol 2004; 41: 129-135.
11. Al-Habori M, Al-Mamari M, Al-Meeri A. Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: Frequency, associated metabolic changes and risk factors. Diabetes Res Clin Pract 2004; 65: 275-281.
12. Siraj ES, Seyoum B, Saenz C, Abdulkadir J. Lipid and lipoprotein profiles in Ethiopian patients with diabeter mellitus. Metabolism 2006; 55: 706-710.
13. Udawit H, Goyal RK, Maheshwari S. Coronary risk and dyslipidemia in type 2 diabetic patients. J Assoc Physicians India 2001; 49; 970-973.
14. Mathura KC, Vaidya B, Gurbacharya DL. Study of serum lipid profile in type 2 diabetic patients attending KMCTH. Nepal Med Coll J 2005; 7: 97-100.
15. Ismail IS, Nazaimoon W. Mohamad W, Letchuman R, Singaraveloo M, Hew FL, et al. Ethnicity and glycaemic control are major determinants of diabetic dyslipidemia in Malaysia. Diabet Med 2001; 18: 501-508.
16. [No authors listed]. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-1687.
17. Khader Y, Bateiha A, El-Khateeb M, Al-Shaikh A, Ajlouni K. High frequency of the metabolic syndrome among northern Jordanians. J Diabetes Complications 2007; 21: 214-219.
18. Brien O, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clinic Proc 1998; 73: 969-976.
19. Taskinen MR, Qauntitative & qualitative lipoproteins abnormalities in diabetes mellitus. Diabetes 1992; 41 (Suppl 1): 12-17.
20. Greg A, SM Grundy SM. The Framingham Heart Study. Diabetes Care 1990; 13: 153-169.
21. Hammoudeh A J, Haddad J, Al-Mousa E. Is dyslipidemia in middle eastern patients with type 2 diabetes mellitus deffirent from that in the west? The Jordan hyperlipidemia and related targets study (JoHARTS-3). Clinical Diabetes 2006; 5: 128-131.
22. Cook CB, Erdman DM, Ryan GJ, Greenlund KJ, Giles WH, Gallina DL, et al. The pattern of dyslipidemia among African Americans with type2 diabetes. Diabetes Care 2000; 23: 319-324.
23. Grant RW, Meigs JB. Frequency and treatment of low HDL cholesterol among primary care patients with type 2 diabetes. Diabetes Care 2007; 30: 479-484.
24. Taskien MR. Diabetic dyslipidemia: From basic research to clinical practice. Diabetologia 2003; 46: 733-749.
25. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
26. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
27. Sharma MD, Pelvic VN. Dyslipidemia in Africa Americans, Hispanics and Whites with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001; 3: 41-45.
28. Aleyassine H, Gardiner RJ, Tonks DN, Koch P. Glycosylated hemoglobin in diabetes mellitus: Correlations with fasting plasma glucose, serum lipids, and glucosuria. Diabetes Care 1980; 3: 508-514.
29. Gonen B, White N, Schonfeld G, et al. Plasma levels of apoprotein B in patients with diabetes mellitus: The effect of glycemic control. Metabolism 1985; 34: 675-679.
30. Agdeppa D, Macaron C, Mallik T, Schnuda N D. Plasma high density lipoprotein cholesterol concentration in thyroid disease, J Clin Endocrinol Metab 1979; 49: 726-729.
31. Caparevi Z, Bojkovi G, Stojanovi D, Ili V. Dyslipidemia and subclinical hypothyroidism. Med Pregl 2003; 56: 276-280.
32. Danese MD, Ladenson PW, Meinert CL, Powe NR, Clinical rewiew 115: effects of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab 2000; 85: 2993-3001.
33. Adler AI, Stevens RJ, Manley SF, Bilous RW, Cull CA, Holma RR, et al. Development and progression of nephropathy in type2 diabetes: observations and modeling from UKPDS, Kidney Int 2003; 63: 225-232.